ACADIA Pharmaceuticals Inc.

ACAD Healthcare Biotechnology

ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024.

Revenue
+22.9%
EPS
−27.9%
Free cash flow
+141.2%

Quarter to September 2026, against a year earlier

21.29 0.05 +0.24%
Market cap
$3.7B
P/E
10.0×
Fwd P/E
33.4×
Dividend yield
—
F-score
6/9
Altman Z
7.90
Beneish M
−0.89
Dividend safety
n/a

ACADIA Pharmaceuticals Inc. (ACAD) Net margin

Alert me on Net margin

ACADIA Pharmaceuticals Inc.'s net margin over the twelve months to 30 September 2026 was 30.1%, down 6.4 percentage points from fiscal 2025 (36.5%). Over the past ten years it has ranged from −269,578.7% (fiscal 2015) to 36.5% (fiscal 2025) — the current reading is the highest in ten years. That is above the Biotechnology industry median of 0.00% and above the Healthcare sector median of 0.00%.

Net margin, annual

Embed this chart

Annual newest first

Period Net margin Change (points)
FY2025 36.5% 12.85
FY2024 23.6% 32.08
FY2023 −8.44% 33.32
FY2022 −41.8% (7.09)
FY2021 −34.7% 29.07
FY2020 −63.7% 5.64
FY2019 −69.4% 40.18
FY2018 −109.6% 122.15
FY2017 −231.7% 1,334.23
FY2016 −1,565.9% 268,012.75

Quarterly newest first

Period Net margin Change (points)
Sep 2026 15.6% 5.41
Jun 2026 10.2% 8.87
Mar 2026 1.36% (94.97)
Dec 2025 96.3% 70.57
43 more quarters

Against its own ten years

Low −269,578.7% High 36.5%
Ten-year median −63.7%
Current reading's percentile 93

Net margin against peers

What Net margin is

Net Profit Margin tells an investor how much of each unit of revenue ends up as profit for shareholders after all costs, interest and taxes.

Net Income Allotted to Shareholders ÷ Revenue

The full definition of Net margin →

More on ACAD